Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.61 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL58545 | 0.85 | CYP3A4 (0.60) | CYP3A4TRPA1GABRA1GABRB2TDP1 | |
| SCHEMBL29796026 | 0.82 | CYP3A4 (0.50) | CYP3A4TRPA1GABRA1GABRB2TDP1 | |
| SCHEMBL9551404 | 0.82 | CYP3A4 (0.50) | CYP3A4TRPA1GABRA1GABRB2TDP1 | |
| SCHEMBL11851275 | 0.81 | CYP3A4 (0.49) | CYP3A4TRPA1GABRA1GABRB2 | |
| SCHEMBL29449627 | 0.80 | ALDH1A1 (0.46) | CYP3A4GABRA1GABRB2TDP1ALDH1A1 | |
| SCHEMBL17649855 | 0.80 | ALDH1A1 (0.46) | CYP3A4GABRA1GABRB2TDP1ALDH1A1 | |
| SCHEMBL29862583 | 0.79 | CYP3A4 (0.54) | CYP3A4TRPA1GABRA1GABRB2TDP1 | |
| SCHEMBL29440559 | 0.79 | CYP3A4 (0.79) | CYP3A4TRPA1GABRA1GABRB2TDP1 | |
| SCHEMBL93192 | 0.79 | CYP3A4 (0.79) | CYP3A4TRPA1GABRA1GABRB2TDP1 | |
| SCHEMBL93182 | 0.79 | CYP3A4 (0.54) | CYP3A4TRPA1GABRA1GABRB2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113248506-A | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith | 西格诺药品有限公司 | 2021-08-13 | — | — | CN | disclosed |
| CN-107001372-B | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith | 西格诺药品有限公司 | 2021-04-27 | — | — | CN | disclosed |
| EP-3543242-A1 | 8,9-DIHYDROIMIDAZOLE[1,2-A]PYRIMIDO[5,4-E]PYRIMIDINE-5(6H)-KETONE COMPOUND | Impact Therapeutics, Inc (CN) | 2019-09-25 | — | — | EP | disclosed |
| CN-105688858-B | A kind of Amylose Chiral Stationary Phase and preparation method thereof | 南京茂甘仪器科技有限公司 | 2018-07-20 | — | — | CN | disclosed |
| WO-2018090939-A1 | 8,9-DIHYDROIMIDAZOLE[1,2-A]PYRIMIDO[5,4-E]PYRIMIDINE-5(6H)-KETONE COMPOUND | 上海瑛派药业有限公司 | 2018-05-24 | — | — | WO | disclosed |
| CN-105688858-A | Amylose chiral stationary phase and preparation method thereof | 南京泛海易隆生物化学科技有限公司 | 2016-06-22 | — | — | CN | disclosed |
| CN-104841408-A | Cyclodextrin chiral stationary phase, and preparation method and application thereof | NANJING LONG TERM ALLIANCE PHARMACEUTICAL & CHEMICALS TECHNOLOGY CO LTD | 2015-08-19 | — | — | CN | disclosed |
| CN-104303054-A | Separating agent | DAICEL CORP | 2015-01-21 | — | — | CN | disclosed |
| US-7741479-B2 | Urea inhibitors of MAP kinases | LOCUS PHARMACEUTICALS, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| EP-1828169-A2 | UREA INHIBITORS OF MAP KINASES | Locus Pharmaceuticals, Inc. (US) | 2007-09-05 | — | — | EP | disclosed |
| US-20060167247-A1 | Urea inhibitors of MAP kinases | LOCUS PHARMACEUTICALS, INC. | 2006-07-27 | — | — | US | disclosed |
| WO-2006062982-A2 | UREA INHIBITORS OF MAP KINASES | LOCUS PHARMACEUTICALS, INC. (US) | 2006-06-15 | — | — | WO | disclosed |
| EP-0860433-B1 | QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF GROWTH FACTOR RECEPTOR ORIGINATING IN PLATELET AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | KIRIN BREWERY (JP) | 2002-07-03 | — | — | EP | disclosed |
| US-6143764-A | ETHER DERIVATIVES OF QUINOLINE, ANTITUMOR AGENTS | KIRIN BEER KABUSHIKI KAISHA (JP) | 2000-11-07 | — | — | US | disclosed |
| US-6060484-A | Anti-viral method | ELI LILLY AND COMPANY (US) | 2000-05-09 | — | — | US | disclosed |
| EP-0860433-A1 | QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF GROWTH FACTOR RECEPTOR ORIGINATING IN PLATELET AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 1998-08-26 | — | — | EP | disclosed |
| WO-1997041846-A1 | ANTI-VIRAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 1997-11-13 | — | — | WO | disclosed |
| EP-0806205-A2 | Urea, thiourea and guanidine compounds and their use as anti-viral agents | ELI LILLY AND COMPANY (US) | 1997-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167247-A1 | Urea inhibitors of MAP kinases | MAPK1, MAP3K1, MAP3K20 | CYP3A4 3548/4885TRPA1 2806/4885GABRA1 4835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.